Rostec and the Perm Krai signed a memorandum on co-operation in implementation of two large investment projects. Within the partnership, a new vaccine production will be opened and release of blood plasma-based drugs including COVID-globulin for the coronavirus infection treatment will be arranged in Perm.

Large-scale projects will be implemented based on the Perm subsidiary of NPO Microgen (the enterprise is a part of Pharmaceutical holding Nacimbio of Rostec State Corporation). As a result of their implementation, a new production facility for DTaP vaccines will be built, moreover, blood products manufacturing will be modernized and its facilities will be expanded.

Dmitry Makhonin, Governor of the Perm Krai, commented:

In partnership with Rostec, the manufacturing of key groups of drugs had been incrementally modernized at the Nacimbio Perm site. This work will allow producing polycomponent inactivated vaccines and highly refined blood products, needed in domestic public health, in industrial-scale volumes.

Production of DTaP drugs with acellular pertussis component is planned to be arranged in the new facility of NPO Microgen subsidiary, and a base to consolidate domestically-produced 5- and 6-component DTaP vaccines, including new pentavaccine containing five components: against diphtheria, tetanus, pertussis, hepatitis B, and haemophilus influenza, is also planned to be created.

The project of blood products manufacturing modernization stipulates the implementation of an improved technique of chromatographic purification of immunoglobulins that allows obtaining highly refined drugs. This technique has already underlain the Nacimbio holding new development – COVID-globulin.

Aleksander Nazarov, Deputy CEO of Rostec State Corporation, said:

COVID-globulin for moderate and severe forms of the coronavirus infection is planned to be manufactured just at the new production facility in Perm. After modernization, the enterprise will be able to process up to 200 tons of donor plasma every year.

COVID-globulin is the world’s first registered drug with anti-COVID-19 antibodies based on coronavirus convalescent blood plasma. The drug neutralizes the virus and helps the body to fight the disease.

Perm subsidiary of NPO Microgen is one of the largest production sites of Pharmaceutical holding Nacimbio of Rostec State Corporation. Its production portfolio includes about 45 titles of drugs, including DTaP-containing combination vaccines and blood products.